SLE 6000 & OxyGenie® Japan approval & £400k Order

RNS Number : 3165S

Inspiration Healthcare Group PLC

16 March 2021

 

 

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

SLE 6000 and OxyGenie ® approved for use in Japan

with initial order for c.£400,000

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, is pleased to announce that SLE Ltd, the specialist neonatal ventilator manufacturer it acquired in July 2020, has received Japanese regulatory approval for the enhanced SLE6000.  The approval is for the top of the range SLE6000 model that includes various features such as enhanced High Frequency Oscillatory Ventilation designed for use with critically ill infants as well as the OxyGenie ® patented oxygen control algorithm which helps maintain infants at their targeted oxygen saturation levels, volume targeted ventilation, End-Tidal CO₂ monitoring and greater non-invasive modes. This product has been registered for use in Japan and the Company's Japanese distributor has placed an initial order totalling c.£400,000 for immediate despatch. 

Neil Campbell, Chief Executive Officer, commented: "We are delighted to have received this significant order and the successful registration of these products in Japan and to see that our global reach continues to expand as the advanced technologies we have developed are adopted in the leading neonatal Intensive care units all over the world." 

Enquiries:

Inspiration Healthcare Group plc Neil Campbell, Chief Executive Officer Jon Ballard, Chief Financial Officer	Tel: [phone]
Nominated Adviser & Broker Cenkos Securities plc Mark Connelly Stephen Keys	Tel: [phone]
Cadogan PR  Alex Walters [e-mail]	Tel: [phone]

About Inspiration Healthcare   http://www.inspiration-healthcare.com

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres. The Company provides high-quality, innovative products to patients around the world which help to improve patient outcomes, and it actively invests in innovative product opportunities and disruptive technologies.

Through investment in research and development the Company has six key own-brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally, the Company has a range of products for maintaining normothermia pre- during and post-surgery.

In September 2019, the Company acquired   Vio Holdings a designer, manufacturer and supplier of single-use respiratory products and sterile medical consumables   for £3.7 million and in   June 2020 the Company acquired SLE, a   leading global provider of neonatal ventilation products for   £18 million.       Over 90% of SLE's revenues are generated from sales outside of the UK with a significant proportion of these in the Asia Pacific and the Middle East. When combined, the Group generates approximately 60 per cent. of its revenue from exports.

With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.

In the U.K. and Ireland, the Company has a direct sales team selling Inspiration Healthcare Branded and complementary products from third parties, with an additional range of home healthcare products.  This is supported by Technical Support for planned preventative maintenance and emergency assistance.

Further information on Inspiration Healthcare can be seen at   www.inspiration-healthcare.com

 

END

 

 

REAFZGMFVKVGMZM